Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this retrospective study, oral isotretinoin monotherapy effectively achieved remission in 82% of patients with folliculitis decalvans, with those receiving ≥0.4 mg/kg/day for ≥3 months experiencing better outcomes and less frequent relapse.

S-1 treatment led to a complete response in pancreatic cancer with manageable side effects.

This study found that mesotherapy with dutasteride effectively reduced or stopped hair loss and promoted new hair growth in males with androgenetic alopecia.

This article discusses the controversy surrounding mesotherapy for hair growth, highlighting the lack of rigorous clinical trials, and reports no new research findings.

This study found that dutasteride mesotherapy increased the diameter of existing hair in five Mexican men with androgenetic alopecia, without reported side effects.

This article discusses the withdrawal of bamlanivimab monotherapy's emergency use authorization in the U.S. due to evolving COVID-19 variants and offers no new clinical data.

This study found that microneedling monotherapy significantly increased hair count more than topical minoxidil in androgenetic alopecia, with combination therapy of microneedling and minoxidil being even more effective. Further research is needed to evaluate microneedling's safety and efficacy as a monotherapy.

This study found that oral tofacitinib monotherapy improved nail changes in 73.3% of adults with moderate-to-severe alopecia areata over a median period of 5 months, but nail improvement was not linked to the severity of hair loss or hair regrowth.

This study found that valproate sustained-release monotherapy provided effective short-term seizure control and was well tolerated in newly-diagnosed epileptic patients with partial seizures in the Gulf Cooperation Council countries.

This review examined three studies on dermaroller monotherapy for hair loss, finding inconsistent efficacy and diverse methods, with risks of follicular damage and infection noted; standardized protocols are urgently needed for safe practice.

This meta-analysis found that PRP monotherapy improved hair density in androgenetic alopecia patients but did not affect hair diameter, with stronger effects observed in male subjects.

This review discusses the development of valproate as an effective monotherapy for controlling generalized seizures and reports no new clinical results.

This chapter summarizes the efficacy of NB-UVB monotherapy for vitiligo and notes that patients treated with tacrolimus showed significantly better repigmentation.

This case report documents the first use of bimekizumab as monotherapy for dissecting cellulitis of the scalp, where a 27-year-old man experienced significant symptom relief without adverse effects after failing standard treatments.

This study found that for managing early-onset androgenetic alopecia in men, minoxidil monotherapy is cost-effective at a $50,000 willingness-to-pay threshold, while combining minoxidil with platelet-rich plasma becomes cost-effective at a $100,000 threshold.

This case collection reports that 15% azelaic acid gel can be effectively used as a monotherapy to treat mild-to-moderate adult female acne.

This study found that women with epilepsy on carbamazepine and sodium valproate monotherapy experienced more significant weight gain but showed no difference in PCOS incidence compared to phenytoin users; elevated TSH levels were more common among those on sodium valproate.

In this study, baricitinib was used as monotherapy to treat a 21-year-old woman with severe alopecia areata, resulting in significant hair regrowth and reduced alopecia severity within three months, suggesting its effectiveness and potential as a robust treatment option for this condition.

In this study, indications for monotherapy with 5-alpha-reductase inhibitors, such as finasteride and herbal drugs, were developed based on clinical and morphological changes in patients with benign prostatic hyperplasia.

In this study, Convulsofin was effective as monotherapy for generalized primary epilepsy and as adjunctive treatment for therapy-resistant secondary and partial epilepsy, though side effects like gastrointestinal issues and weight gain were noted.

In this study, sodium valproate achieved complete seizure control in 82% of children as monotherapy, with higher plasma levels potentially linked to resistant cases.

This review discusses the challenges of diagnosing and treating pediatric bipolar disorder and highlights the potential benefits of combined psychopharmacological treatments, noting no long-term efficacy from mood stabilizer monotherapy.

This review discusses trials on therapies for benign prostatic hyperplasia and reports that combination treatment is more effective than monotherapy for symptom relief and slowing disease progression in men with moderate to severe symptoms and enlarged prostate glands.

This study suggests that neither autologous platelet-rich plasma nor 5% topical minoxidil reliably outperforms the other as a monotherapy for male androgenetic alopecia, with combination therapy often showing superior outcomes.

In this systematic review and meta‐analysis, botulinum toxin monotherapy was found to significantly increase hair density in patients with androgenetic alopecia, with optimal effects observed using a 100-unit dose every six months. These findings suggest potential efficacy but should be confirmed in larger, placebo-controlled trials.

This case report describes a patient with both rheumatoid arthritis and alopecia areata who showed improvement in both conditions after treatment with baricitinib monotherapy, highlighting the importance of personalized treatment approaches in managing co-occurring autoimmune diseases.

The study concluded that dutasteride 0.5 mg daily for 24 weeks was the most effective monotherapy for increasing hair density in men with androgenetic alopecia, compared to other interventions.

In this study, most surveyed physicians were aware of the meningioma risk linked to cyproterone acetate monotherapy, but many did not recall receiving updated safety communications.

This study will explore whether combination therapy with either dutasteride or finasteride and an α1 blocker is more effective than monotherapy for treating BPH, but it reports no new results.

This meeting review discusses recent advances in systemic psoriasis treatments, emphasizing the impact of dimethylfumarate monotherapy on understanding psoriasis and treatment strategies; it reports no new clinical results.